These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N. Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521 [Abstract] [Full Text] [Related]
5. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Houthoofd SA, Morrens M, Sabbe BG. Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365 [Abstract] [Full Text] [Related]
6. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, Jernigan TL, Baaré WF. Psychiatry Res; 2007 Apr 15; 154(3):199-208. PubMed ID: 17360162 [Abstract] [Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Clin Ther; 2008 Dec 15; 30(12):2378-86. PubMed ID: 19167596 [Abstract] [Full Text] [Related]
8. Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. Yoshimura R, Kakihara S, Umene-Nakano W, Sugita A, Hori H, Ueda N, Nakamura J. Hum Psychopharmacol; 2008 Jun 15; 23(4):327-32. PubMed ID: 18273830 [Abstract] [Full Text] [Related]
9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. J Clin Psychiatry; 2004 Aug 15; 65(8):1084-9. PubMed ID: 15323593 [Abstract] [Full Text] [Related]